Core Insights - PAVmed Inc. completed a private placement equity financing for its subsidiary Veris Health, raising $2.5 million at a pre-money valuation of approximately $35 million [1][2][3] Group 1: Financing Details - Veris Health sold shares at $1.40 per share, with proceeds aimed at advancing its implantable physiological monitor through FDA clearance expected in 2026 [2][3] - The financing follows a previous $2.4 million round completed earlier in the year, indicating ongoing investor interest and confidence in Veris Health's potential [1][2] Group 2: Product and Technology - Veris Health focuses on personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices [2][4] - The Veris Cancer Care Platform integrates remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration to enhance patient care [4][5] Group 3: Strategic Importance - The financing is seen as a significant milestone for both PAVmed and Veris, providing necessary capital to fund the development and commercialization of the implantable physiological monitor [3][4] - The monitor is expected to serve as a key differentiator in the market, enhancing personalized care in conjunction with the Veris Cancer Care Platform [3][5]

Company Overview - Jaan Health has developed the AI-powered proactive care platform Phamily© to address the clinical and financial needs of healthcare stakeholders [1][2] - The company has secured over $25 million in funding, including $15 million in non-dilutive growth capital from Level Structured Capital [1][2] Product and Market Impact - Phamily enables healthcare organizations to deliver high-quality, proactive care management at scale, serving over 150 healthcare organizations and hundreds of thousands of patients with more than 250 chronic condition diagnoses [2][5] - The platform has improved patient outcomes and provider profitability while significantly reducing the total cost of care for payors [2][5] Growth Strategy - The new funding will allow Jaan Health to expand Phamily's market leadership in virtual care, penetrate new market segments, and make key hires to support rapid growth [2][3] - The company aims to extend the benefits of Phamily to millions more patients across the United States [2] Industry Context - Jaan Health stands out in a crowded health tech market due to its proprietary data sets, operational strength, and capital efficiency [3] - The platform addresses the challenges faced by healthcare systems, particularly in managing chronic diseases amid labor shortages and rising costs [2][3]

Comprehensive Healthcare Systems Secures New York City Based Client on Novus360 for Streamlined, High Value Utilization Management SolutionsJune 24, 2025 7:01 AM EDT | Source: Comprehensive Healthcare Systems Inc.Calgary, Alberta--(Newsfile Corp. - June 24, 2025) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (the "Company" or "CHS"), a leading provider of healthcare benefits administration software and services, is pleased to announce the expansion of its client portfolio with a 5 year r ...

[Music] Today I want you to consider the possibility that you are one of the nine out of 10 people listening to this talk right now who have codependent thoughts, beliefs, and behaviors. Does that make you a little uncomfortable? Okay, good. Are you the one shaking their head saying, "Not me. I'm so independent. " Okay. Most people don't realize what codependency is. They just know they don't want to be it or have it. Most people think it's about an unhealthy attachment to another person, which is part of i ...

Building information modeling beam. Does it mean anything to you. What if I told you it is one of the skill that can help you compete and fast track through your career making you instantly employable placing you ahead of hundreds of graduates.a skill many architectural and engineering students heard about but few truly explore and it changed my life. A very good afternoon ladies and gentlemen. My name is Iwan Feros and I just graduated few months in August at from UTM Sander.Not too long ago, I was where m ...

Thank you. So when I was 19, I was in Montreal. I was an undergrad student and I managed to get sick with the flu.So I sat down and I Googled, "Is flu going to kill me?" And Google Google brought up Wikipedia. Wikipedia said no. So, I stayed at home for 3 days eating my typical diet of ramen and water and uh didn't get better.So, I decided to go to the hospital. Now, has anyone here been to a hospital or an emergency room. Raise of hands.So, who thought it was a really good use of their time. Very efficient ...

قبل كم سنه فقدت شخص عزيز علي بديت وراها افكر هوايه افكر وافكر 24 ساعه صار عندي خوف بديت احس هذا ياثر على صحتي صرت اتعب طول اليوم صار عندي شد عضلي رح الطبيب قال لي عندك شيء اسمه انكزايتي شنو يقصد؟ رحت بحثت حتى اقدر افهم نفسي اكثر لقيت معلومه غريبه اول مره اقراها هاي المعلومه تقول انه داخلنا اكو ثلاث اشخاص شخص اناني يعبر عن رغباته باي طريقه ممكنه شخص ملتزم بالقوانين الدين والاخلاق والشخص الثالث اللي هو يحاول يلقى الحل الامثل ويوازن بيناتهم الشخص الاول هو الاد او الهو الشخص الثاني هو السوبر ايجو او الانا العلي ...

Core Insights - BioStem Technologies, Inc. has completed patient enrollment for a clinical trial comparing BioREtain® Amnion Chorion (BR-AC) to standard care for non-healing diabetic foot ulcers (DFUs) [2][3] - The BR-AC-DFU-101 study aims to evaluate the effectiveness of BR-AC in achieving complete wound closure over a 12-week period [3][5] - Topline results from the study are expected in Q4 2025, with the trial initiated in Q4 2024 across 11 sites in the U.S. [3][4] Company Overview - BioStem Technologies focuses on developing, manufacturing, and commercializing placental-derived products for advanced wound care [2][10] - The company utilizes a proprietary BioREtain processing method that preserves the natural properties of perinatal tissue [8][10] - BioStem's quality management systems are accredited by the American Association of Tissue Banks and adhere to Good Tissue Practices and Good Manufacturing Processes [11] Clinical Trial Details - The primary objective of the BR-AC-DFU-101 study is to determine if the combination of standard care and BR-AC leads to a higher probability of complete wound closure compared to standard care alone [5] - Secondary outcome measures include comparing treatment group differences in wound closure rates, wound area, and volume [7] - The study has enrolled 71 patients, exceeding the initial target of 60 [3][4] Market Context - Diabetic foot ulcers affect approximately 15% of individuals with diabetes, with 6% requiring hospitalization due to complications [5] - The economic burden of DFUs in the U.S. is significant, with annual treatment costs estimated between $9 billion and $13 billion [6] - In 2023, 2.2 million patients received treatment for DFUs, with numbers projected to rise [6]

Core Insights - Tempus AI reported $193.8 million in Genomics revenues for Q1 2025, marking an increase of nearly 89% year over year, driven by a 20% growth in oncology test volumes and higher average revenue per test due to increased Medicare reimbursement rates [1][8] - The company is set to launch a new liquid biopsy assay, xM for treatment response monitoring, which will track changes in tumor fraction during immune-checkpoint inhibitor therapies, potentially influencing treatment decisions [2] - Tempus is also preparing to launch its first whole-genome sequencing test, Xh, aimed at detecting clinically relevant variants in hematological oncology by next year [3] - A companion diagnostic test is being developed in collaboration with Verastem Oncology, leveraging Tempus' FDA-approved xT CDx assay in clinical trials for ovarian cancer treatment [4] Industry Updates - Guardant Health reported a 20% year-over-year growth in oncology revenues, with a 25% increase in test volumes, and launched a hereditary cancer test [5] - Exact Sciences is experiencing strong international adoption of its Oncotype DX genomic test and has launched Cologuard Plus, which is expected to reduce false positives significantly [6] Financial Performance - Tempus AI shares have increased by 105.3% year to date, outperforming the industry average growth of 28% [7] - The company is trading at a forward Price-to-Sales ratio of 8.60X, compared to the industry average of 6.02X [9] - The Zacks Consensus Estimate for Tempus AI's 2025 earnings has been trending upward over the past 90 days, indicating positive market sentiment [11]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Pfizer (NYSE: PFE ) is arguably the biggest victim of the radical new healthcare policies being brought about by the Trump administration, and in my view, this means that its dividend - currently yielding >7% perTh ...